Domainex and scientists led by Professor Alan Ashworth of the Breakthrough Breast Cancer Research Centre at the Institute of Cancer Research have discovered drug-like compounds that inhibit an enzyme from the PARP superfamily

Domainex will now provide lead optimization services that will assist Ashworth's team to develop drug candidates targeting this enzyme. The programme recently received a £4 million research grant under the Wellcome Trust's Seeding Drug Discovery Initiative.

Download Press release